Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Roxifiban SCHEMBL344302 | 1.00 | ITGB3 (1.00) | ITGB3ITGA2B | |
| Roxifiban SCHEMBL919675 | 0.98 | ITGB3 (0.95) | ITGB3ITGA2B | |
| SCHEMBL7213400 | 0.94 | ITGB3 (1.00) | ITGB3ITGA2B | |
| Roxifiban SCHEMBL50632 | 0.93 | ITGB3 (0.86) | ITGB3ITGA2B | |
| SCHEMBL7220986 | 0.91 | ITGB3 (0.83) | ITGB3ITGA2B | |
| SCHEMBL7407564 | 0.89 | ITGB3 (0.80) | ITGB3ITGA2B | |
| SCHEMBL7413714 | 0.89 | ITGB3 (0.80) | ITGB3ITGA2B | |
| SCHEMBL7214664 | 0.86 | ITGB3 (0.76) | ITGB3ITGA2B | |
| SCHEMBL7217243 | 0.86 | ITGB3 (0.76) | ITGB3ITGA2B | |
| SCHEMBL7214752 | 0.86 | ITGB3 (0.76) | ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11685717-B2 | Polypeptide integrin antagonists | THE GENERAL HOSPITAL CORPORATION (US) | 2023-06-27 | — | — | US | disclosed |
| US-11643393-B2 | Integrin antagonists | THE GENERAL HOSPITAL CORPORATION (US) | 2023-05-09 | — | — | US | disclosed |
| US-20220081398-A1 | Integrin Antagonists | THE GENERAL HOSPITAL CORPORATION | 2022-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220081398-A1 | Integrin Antagonists | ITGA2B, ITGA2, ITGB2 | ITGB3 9/4885ITGA2B 1/4885 |
| US-11685717-B2 | Polypeptide integrin antagonists | ITGA2B, ITGAV, ITGB2 | ITGB3 5/4885ITGA2B 1/4885 |
| US-11643393-B2 | Integrin antagonists | ITGA2B, ITGA2, ITGB2 | ITGB3 9/4885ITGA2B 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.